5 completed, 4 recruiting. 5 Phase 2, 4 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Completed 2 |
| Not applicable | 4 | Completed 3, Recruiting 1 |
Follow 2-hydroxybenzylamine: new trials by email Literature Review of 2-hydroxybenzylamine trials Research Report on 2-hydroxybenzylamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans 2-hydroxybenzylamine, Placebo - Salt Sensitivity of Blood Pressure, High Blood Pressure | Phase 2 | Recruiting | Vanderbilt University Medical Center | 20 | 2026-10-30 | 2026-11-04 |
| 2-HOBA in Systemic Lupus Erythematosus 2-HOBA acetate (2-Hydroxybenzlamine acetate), Placebo - Systemic Lupus Erthematosus (SLE) | Phase 2 | Recruiting | Vanderbilt University Medical Center | 42 | 2026-05-15 | 2026-05-22 |
| This Study Investigates β-hydroxy-β-methylbutyrate (HMB) and 2-hydroxybenzylamine (2-HOBA), When Administered Either Individually or in Combination Contributes to an Increased Quality of Health, Specifically Improving Muscular Strength and Cognitive Functioning in Adults Over the Age of 65. β-Hydroxy-β-methylbutyrate, 2-hydroxybenzylamine, β-Hydroxy-β-methylbutyrate and 2-hydroxybenzylamine - Muscle, Cognitive Functioning | Not applicable | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 120 | 2026-03-06 | 2026-05-14 |
| 2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH) 2-Hydroxybenzylamine, Placebo - Familial Hypercholesterolemia | Phase 2 | Recruiting | Vanderbilt University Medical Center | 72 | 2024-02-14 | 2026-08-07 |
| 2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis 2-HOBA, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Vanderbilt University Medical Center | 32 | 2022-08-09 | 2026-04-08 |
| 2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation 2-Hydroxybenzylamine, Placebo - Atrial Fibrillation | Phase 2 | Completed | Vanderbilt University Medical Center | 95 | 2020-05-15 | 2024-11-21 |
| 2-HOBA: Multiple Dosing Study in Older Adults 2-HOBA, Placebo - Older Adults | Not applicable | Completed | Metabolic Technologies Inc. | 18 | 2018-05-23 | 2021-12-14 |
| 2-HOBA: Multiple Dosing Study in Healthy Humans 2-HOBA, Placebo - Healthy Volunteers | Not applicable | Completed | Metabolic Technologies Inc. | 18 | 2018-05-23 | 2019-08-13 |
| Brain Penetrance of 2-HOBA in Humans 2-HOBA - Healthy Adults | Not applicable | Completed | Metabolic Technologies Inc. | 3 | 2018-05-23 | 2019-02-20 |
Hypertension (2) · Arthritis, Rheumatoid (1) · Atrial Fibrillation (1) · Hyperlipoproteinemia Type II (1) · Inflammation (1) · Lupus Erythematosus, Systemic (1)
Vanderbilt University Medical Center (5) · Metabolic Technologies Inc. (3) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1)
United States (8) · Canada (1)
John A Rathmacher, PhD (3) · Ben Shoemaker, MD (1) · Gustavo Duque, Medical Doctor (1) · MacRae F. Linton, MD (1) · Michelle J Ormseth, MD, MSCI (1) · Michelle Ormseth, MD, MSCI (1)
PMID 31907026, PMID 11230313, PMID 12147930, PMID 1846122, PMID 1860713, PMID 1879381, PMID 34454591, PMID 3522418, PMID 37534363, PMID 37675576, PMID 41052782
R44AG055184 (3), P01HL116263 (1), P01HL174442 (1)